LBLisa H. Buckley

Lisa H. Buckley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lisa H. Buckley has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identifying Pediatric Rheumatic Disease Through Computable Phenotypes and Informatics Tools

    by Alysha Taxter, Matthew Basiaga, Raj Pooni, Caitlan Pinotti, Lisa Buckley

    Objective: This multi-site study developed and validated a predictive computable phenotype to identify children with rheumatic disease using on-demand, self-service electronic health record (EHR) reporting tools.Method: Four sites using the same EHR created standardized queries. Inclusion covariates included combinations of diagnosis, age, department (pediatric rheumatology), encounter type (office visit, telemedicine), visit type (new patient, return visit), and care team. The queries were initially derived and tested retrospectively over two weeks, with query results manually compared to clinic schedules by pediatric rheumatologists. The highest-performing query was then validated both prospectively and retrospectively. Query performances are reported using descriptive statistics and logistic regression with clustering by site.Results: Of the 674 patient visits included, 589 (88%) patient visits were prospectively evaluated, 517 (77%) patient visits were retrospectively evaluated, and 433 (64%) patient visits were included in both queries. Prospective queries had a sensitivity of 86%, specificity of 96%, positive predictive value (PPV) of 92%, and negative predictive value (NPV) of 92%, with an area under the curve (AUC) of 0.92. Retrospective queries had a sensitivity of 80%, specificity of 97%, PPV of 95%, and NPV of 87%, with an AUC of 0.91. Age and return visit type, but not female sex, were statistically associated with a rheumatic diagnosis and being present on both queries in univariate analysis. Conclusions: An EHR-based computable phenotype can efficiently and accurately identify eligible patients with rheumatic disease. Such queries can potentially be utilized for pre-visit planning and research recruitment, reducing the need for manual chart review.

  • Incidence Rates of Psoriasis in Children With Inflammatory Bowel Disease and Juvenile Arthritis Treated With Tumor Necrosis Factor Inhibitors and Disease-Modifying Antirheumatic Drugs

    by Katelyn Baggett, Timothy G. Brandon, Rui Xiao, Zachary Valenzuela, Lisa H. Buckley, Pamela F. Weiss

    Objective: To estimate the differential effect of tumor necrosis factor inhibitor (TNFi) therapies and presence or absence of conventional synthetic disease-modifying antirheumatic drugs (DMARDs) on the incidence of psoriasis (PsO) in children with inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), and chronic nonbacterial osteomyelitis (CNO).Methods: This was a retrospective cohort study from 2008 to 2020. TNFi and DMARD exposures were dichotomized as ever/never. The primary outcome was incident PsO. Incidence rates (IRs) of PsO were stratified by underlying diagnosis, TNFi agent, and DMARD use. Poisson regression was used to assess the IR ratios (IRRs) between exposure groups.Results: There were 5088 children who met the inclusion criteria: 3794 (75%) had IBD, 1189 (23%) had JIA, and 105 (2%) had CNO. Of the 2023 children with TNFi exposure, 613 (30%) and 1410 (70%) were with or without a DMARD, respectively. When controlling for DMARD, sex, and family history of PsO, the IRR of developing PsO in patients exposed to adalimumab (ADA) was 2.70 times higher (95% CI 1.53-4.75; P < 0.001) than those who did not receive any TNFi treatment. IRR was lower, but not significantly different, for patients exposed to infliximab (IFX; IRR 2.34, 95% CI 1.56-3.51; P < 0.001) and etanercept (ETN; IRR 2.21; 95% CI 1.17-4.21; P = 0.006) compared to TNFi-unexposed patients. IRR of TNFi exposure was lower by 0.25 (P < 0.001) in DMARD-exposed patients compared to non–DMARD-exposed patients.Conclusion: IRR of TNFi-induced PsO was not significantly different among ADA, IFX, and ETN. However, for patients with exposure to any of the TNFi evaluated, the IRR was significantly lower in those also exposed to a DMARD.


  • Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases

    by Lisa H. Buckley, Rui Xiao, Marissa J. Perman, Andrew B. Grossman, Pamela F. Weiss

    Objective: To estimate the incidence rate (IR) of psoriasis in children with inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), and chronic noninfectious osteomyelitis (CNO) with tumor necrosis factor inhibitor (TNFi) exposure as compared to children without TNFi exposure and to the general pediatric population.Methods: This was a single‐center retrospective cohort study of children with IBD, JIA, or CNO from 2008 to 2018. TNFi exposure was defined as a prescription for adalimumab, etanercept, infliximab, certolizumab, or golimumab, and the primary outcome was incident psoriasis. IRs and standardized incidence ratios (SIRs) were calculated. Cox proportional hazards models were used to assess the association of psoriasis with TNFi exposure and other risk factors.Results: Of the 4,111 children who met inclusion criteria, 1,614 (39%) had TNFi exposure and 2,497 (61%) did not, with 4,705 and 6,604 person‐years of follow‐up, respectively. There were 58 cases (IR 12.3 per 1,000 person‐years) and 25 cases (IR 3.8 per 1,000 person‐years) of psoriasis in children with and without TNFi exposure, respectively. The SIR was 18 (95% confidence interval [95% CI] 15–22) overall, 30 (95% CI 23–39) for children with TNFi exposure, and 9.3 (95% CI 6.3–14) for children without TNFi exposure. The hazard ratio of psoriasis comparing TNFi exposure to no TNFi exposure was 3.84 (95% CI 2.28–6.47; P < 0.001).Conclusion: Children with IBD, JIA, and CNO had an increased rate of psoriasis compared to the general pediatric population, with the highest rate in those with TNFi exposure.


  • Outcome Monitoring and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis

    by Lisa Buckley, Eileen Ware, Genna Kreher, Lisa Wiater, Jay Mehta, Jon M. Burnham

    Objective.: Inconsistent assessment and treatment may impair juvenile idiopathic arthritis (JIA) outcomes. We aimed to improve polyarticular JIA (rheumatoid factor–positive and –negative) outcomes by standardizing point-of-care disease activity monitoring and implementing clinical decision support (CDS) to reduce treatment variation.Methods.: We performed a quality improvement initiative in an outpatient pediatric rheumatology practice. The interventions, implemented from April to November 2016, included standardized disease activity measurement, disease activity target review, and phased introduction of polyarticular JIA CDS to guide medication selection, dosing, treatment duration, and tapering. Process measures included visit-level target attestation (goal: 50%) and CDS use (goal: 15%). Our goal was to reduce the polyarticular JIA clinical Juvenile Arthritis Disease Activity Score (cJADAS-10) by at least 10%. Included patients had at least 2 visits from April 2016 through July 2017, and were classified as having early (≤ 6 mos) or established disease (> 6 mos).Results.: Patients with polyarticular JIA (n = 97; 81% established disease) were observed for 10.3 months (interquartile range: 6.4–12.3). Target attestation and CDS use occurred in a mean of 77% and 45% of polyarticular JIA visits, respectively. The median cJADAS-10 decreased significantly in both early (16.5 to 2.7, p < 0.001) and established polyarticular JIA (2.1 to 1.0, p = 0.01). A high proportion of patients with early disease received biologic therapy (73.7%). In established disease, although prescription of nonbiologic and biologic disease-modifying antirheumatic drugs remained similar overall, adalimumab prescribing increased (12.8% to 23.1%, p = 0.008).Conclusion.: Implementation of structured disease activity monitoring and CDS in polyarticular JIA was associated with significant reductions in disease activity scores in both early and established disease.